Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Celcuity (NASDAQ:CELC) Stock Declines in a Biotech Risk-Off Session

● No clinical trial update, regulatory development,Earningsreport, financing, partnership, or analyst action has been verified as the driver.

Nitish Kishor | 08 October 2026

Caribou Biosciences (NASDAQ:CRBU) Stock Slides in a Biotech Risk-Off Session

● CRBU shares closed at $0.617 on October 7, 2026, a decline of 45.60% that nearly cut the company'sMarket Valuein half.

Nitish Kishor | 08 October 2026

CEL-SCI (NYSE American:CVM) Stock Slides in a Biotech Risk-Off Session

● CVM shares closed at $2.130 on October 7, 2026, a loss of 22.26% that erased roughly a fifth of the stock's value.

Nitish Kishor | 08 October 2026

Which Quality Healthcare Stock Hides the Biggest Catch: Zevra Therapeutics (NASDAQ:ZVRA), Arbutus Biopharma (NASDAQ:ABUS) or CareDx (NASDAQ:CDNA)?

Zevra Therapeutics (NASDAQ:ZVRA) sells MIPLYFFA for Niemann-Pick disease type C. The screener listsReturn on Equityof 33.44%,Operating Marginof 28.71%, debt to equity of 0.01 and trailing revenue growth of 119.40%. Reported figures are lower: second quarter revenue grew about 53% and first half revenue was …

Vinay Lochav | 08 October 2026

Which Healthcare Gainer Has a Real Catalyst: Intellia (NASDAQ:NTLA), Veradermics (NYSE:MANE), bioAffinity (NASDAQ:BIAF) or DataMeds AI (NASDAQ:MEDS)?

Intellia Therapeutics rose without a verified trigger; the nearest items were a Barclays Sell initiation with a USD 8 target on October 6 and a Wells Fargo Hold with a USD 15 target on October 2, both from an aggregator. The anchor is lonvo-z, …

Vinay Lochav | 08 October 2026

Which Sub-USD 10 Healthcare Name Is Surging: YD Bio (NASDAQ:YDES), Quanterix (NASDAQ:QTRX), Myriad Genetics (NASDAQ:MYGN) or ImmunityBio (NASDAQ:IBRX)?

YD Bio (NASDAQ:YDES) is an ophthalmology and diagnostics company with no approved products. YD Bio traded between USD 3.19 and USD 4.25 through most of September 2026, then closed at USD 3.23 on September 23. A 47.7% jump followed on September 24, and closes …

Vinay Lochav | 08 October 2026

How Veeva Systems (NYSE:VEEV) Grew Revenue and Widened Its AI Plans in Its Fiscal First Quarter

● Non-GAAPNet Incomereached $371.1 million, or $2.24 per diluted share.

Nitish Kishor | 08 October 2026

Why Did Haemonetics (NYSE:HAE) Jump 15.9% on a CSL Update?

Haemonetics furnished an 8-K on October 8, 2026 under its Regulation FD item. It recalled the supply agreement with CSL Plasma, first disclosed on August 18, 2026, that lets CSL use Haemonetics NexSys PCS devices with Persona PLUS technology and buy related disposables in …

Vinay Lochav | 08 October 2026

Why Are Zevra Therapeutics (NASDAQ:ZVRA) Sales Up 53%?

The screener listsReturn on Equityof 33.44%,Operating Marginof 28.71%, debt to equity of 0.01 and trailing revenue growth of 119.40%. Reported figures are lower: second quarter revenue grew about 53% and first half revenue was USD 75.9 million against USD 46.3 million, about 64% higher …

Vinay Lochav | 08 October 2026

Why Did YD Bio (NASDAQ:YDES) Rocket 59% in a Month?

YD Bio traded between USD 3.19 and USD 4.25 through most of September 2026, then closed at USD 3.23 on September 23. A 47.7% jump followed on September 24, and closes of USD 5.73, USD 7.11, USD 7.61, USD 7.42 and USD 7.81 followed …

Vinay Lochav | 08 October 2026
Support

Hi! How can we help you today?

Loading…